Telotristat Etiprate
FDA-approved product (tablet, oral), marketed as Xermelo.
- Registered studies
- 27
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Carcinoid tumor
- Diarrhea
- Neuroendocrine neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Various alimentary tract and metabolism products
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA54.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli54.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae34.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
27registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Telotristat Etiprate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- PimozideExisting use: Psychosis, Tics, Tourette syndrome55.1% AI-predicted activityagainst E. coli15 registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm55.0% AI-predicted activityagainst E. coli50+ registered studies
- RepotrectinibExisting use: Cancer, Neoplasm55.0% AI-predicted activityagainst E. coli17 registered studies
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more54.8% AI-predicted activityagainst E. coli50+ registered studies
- Bosutinib MonohydrateExisting use: Chronic myelogenous leukemia, Myeloid leukemia54.6% AI-predicted activityagainst E. coli2 registered studies
- Ribociclib SuccinateExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 1 more54.5% AI-predicted activityagainst E. coli1 registered study
- Ergoloid MesylatesExisting use: Cardiovascular disease54.5% AI-predicted activityagainst E. coli2 registered studies
- CabotegravirExisting use: HIV infection, HIV-1 infection, Viral disease54.4% AI-predicted activityagainst E. coli50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more54.2% AI-predicted activityagainst E. coli50+ registered studies
- LorlatinibExisting use: Cancer, Lymphoma, Neoplasm and 1 more54.1% AI-predicted activityagainst E. coli50+ registered studies
- TelaprevirExisting use: Chronic hepatitis C virus infection, Viral disease53.9% AI-predicted activityagainst E. coli50+ registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more53.9% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects
NCT02157558 · start 2014-07
Registered record
- Registry ID
- NCT02157558
- Conditions
- Drug Interactions
- Interventions
- Fexofenadine; Telotristat etiprate
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-07
- Completion
- Not recorded
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDrug InteractionsInterventionFexofenadine; Telotristat etipratePhasePhase 1Registry statusCompletedPhase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects
NCT02195635 · start 2014-07
Registered record
- Registry ID
- NCT02195635
- Conditions
- Drug Interactions
- Interventions
- Telotristat etiprate; Octreotide acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-07
- Completion
- Not recorded
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDrug InteractionsInterventionTelotristat etiprate; Octreotide acetatePhasePhase 1Registry statusCompletedAn Open-Label Food Effect Study of Telotristat Etiprate
NCT02157584 · start 2014-06
Registered record
- Registry ID
- NCT02157584
- Conditions
- Healthy
- Interventions
- Telotristat etiprate; Telotristat etiprate
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-06
- Completion
- Not recorded
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionTelotristat etiprate; Telotristat etipratePhasePhase 1Registry statusCompletedA Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects
NCT02147808 · start 2014-05
Registered record
- Registry ID
- NCT02147808
- Conditions
- Drug Interactions
- Interventions
- Telotristat etiprate; Midazolam
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-05
- Completion
- Not recorded
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDrug InteractionsInterventionTelotristat etiprate; MidazolamPhasePhase 1Registry statusCompletedA Thorough QT Study of Telotristat Etiprate
NCT02155205 · start 2014-05
Registered record
- Registry ID
- NCT02155205
- Conditions
- QT Interval
- Interventions
- Telotristat etiprate; Placebo; Moxifloxacin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-05
- Completion
- Not recorded
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionQT IntervalInterventionTelotristat etiprate; Placebo; MoxifloxacinPhasePhase 1Registry statusCompletedTelotristat Etiprate for Carcinoid Syndrome Therapy
NCT02063659 · start 2014-03-11
Registered record
- Registry ID
- NCT02063659
- Conditions
- Carcinoid Syndrome
- Interventions
- Telotristat etiprate; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-03-11
- Completion
- 2016-03-29
- Enrolment
- 76
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCarcinoid SyndromeInterventionTelotristat etiprate; PlaceboPhasePhase 3Registry statusCompletedTelotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
NCT02026063 · start 2014-01-14
Registered record
- Registry ID
- NCT02026063
- Conditions
- Carcinoid Syndrome
- Interventions
- Telotristat etiprate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-01-14
- Completion
- 2018-09-12
- Enrolment
- 124
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCarcinoid SyndromeInterventionTelotristat etipratePhasePhase 3Registry statusCompletedAn Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
NCT01932528 · start 2013-08
Registered record
- Registry ID
- NCT01932528
- Conditions
- Carcinoid Syndrome
- Interventions
- 500 mg [14C]-LX1606
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-08
- Completion
- Not recorded
- Enrolment
- 8
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCarcinoid SyndromeIntervention500 mg [14C]-LX1606PhasePhase 1Registry statusCompletedTELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
NCT01677910 · start 2013-01-08
Registered record
- Registry ID
- NCT01677910
- Conditions
- Carcinoid Syndrome
- Interventions
- Telotristat etiprate; Placebo-matching telotristat etiprate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2013-01-08
- Completion
- 2016-03-21
- Enrolment
- 135
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCarcinoid SyndromeInterventionTelotristat etiprate; Placebo-matching telotristat etipratePhasePhase 3Registry statusCompletedA Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis
NCT01456052 · start 2012-01-30
Registered record
- Registry ID
- NCT01456052
- Conditions
- Ulcerative Colitis
- Interventions
- Telotristat Etiprate; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-01-30
- Completion
- 2013-09-03
- Enrolment
- 59
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUlcerative ColitisInterventionTelotristat Etiprate; PlaceboPhasePhase 2Registry statusCompletedStudy of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
NCT01104415 · start 2010-06-15
Registered record
- Registry ID
- NCT01104415
- Conditions
- Carcinoid Syndrome
- Interventions
- Telotristat etiprate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-06-15
- Completion
- 2014-02-12
- Enrolment
- 15
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCarcinoid SyndromeInterventionTelotristat etipratePhasePhase 2Registry statusCompletedStudy of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
NCT00853047 · start 2009-03
Registered record
- Registry ID
- NCT00853047
- Conditions
- Carcinoid Syndrome
- Interventions
- Telotristat etiprate; Octreotide LAR Depot; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-03
- Completion
- 2014-06
- Enrolment
- 23
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCarcinoid SyndromeInterventionTelotristat etiprate; Octreotide LAR Depot; PlaceboPhasePhase 2Registry statusCompleted